HF
RARE icon

HRT Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

HRT Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.83M Buy
+135,000
New +$3.04M 0.01% 1368

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

HRT Financial's RARE Position: Q1 2026 in Review

HRT Financial increased its Ultragenyx Pharmaceutical (RARE) stake by 22% in Q1 2026, buying an estimated $2.51M and bringing the position to 613,229 shares worth $12.8M. The position accounts for 0.03% of the portfolio, ranked #522.

HRT Financial first reported a position in RARE in Q2 2021 and has held it in 12 quarters since. The position peaked at $15M in Q2 2021. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • HRT Financial held 613,229 shares of Ultragenyx Pharmaceutical worth $12.8M as of Q1 2026.
  • HRT Financial bought 111,550 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.51M.
  • Ultragenyx Pharmaceutical made up 0.03% of HRT Financial's portfolio in Q1 2026, its #522 holding.
  • HRT Financial first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and has held it in 12 quarters since.
  • HRT Financial's Ultragenyx Pharmaceutical position peaked at $15M in Q2 2021.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.